Artivion Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced the successful closing of transactions to exchange approximately $99.5 million in principal amount of its 4.250% Convertible Senior Notes due 2025 for common stock. The exchange agreements resulted in the issuance of 4,334,347 shares of the company's common stock to the note holders, significantly reducing Artivion's outstanding debt and enhancing its balance sheet flexibility. Alongside the exchange, the company made a cash payment of approximately $1.7 million for accrued and unpaid interest. The transaction, advised by J. Wood Capital Advisors LLC, marks an important milestone in Artivion's efforts to strengthen its financial position, leaving only $0.46 million in aggregate principal amount of the notes outstanding.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.